Fatty liver and colorectal polyp risk study
Part of Digestive system, Hormones & metabolism clinical trials.
This study looks at whether certain gene activity in people with fatty liver disease can predict the risk of developing colorectal polyps. It may help doctors find high-risk patients earlier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of fatty liver disease (MAFLD).
- You are between 18 and 70 years old.
- You agree to sign a consent form and follow the study plan.
- You do not have other chronic liver diseases (like hepatitis, cirrhosis, or liver cancer).
- You do not have serious heart, kidney, or lung disease or a bleeding disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new blood test to help diagnose fatty liver disease and liver fibrosis. It aims to see how well the test works compared with a liver biopsy. Your participation could help improve diagnosis for others.
This trial tests a new medicine, HSK31679, for people with MASH (a type of fatty liver disease with inflammation and scarring). It aims to see if the drug can help improve liver health.
This study looks at how a sugar called fructose affects inflammation and metabolism in people with a type of fatty liver disease called MASH. It aims to find out if fructose plays a role in making the disease worse.
This study asks people with metabolic fatty liver disease and liver scarring about their experiences. It aims to learn what matters to you so doctors can improve care.
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
This study looks at how a specific gut bacteria (Ruminococcus gnavus) and the chemicals it makes are linked to a type of fatty liver disease called MAFLD. By joining, you'll help researchers understand this connection, which may lead to better treatments in the future.
Hear when a new MASH - Metabolic Dysfunction-Associated Steatohepatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.